A detailed history of Ensign Peak Advisors, Inc transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 69,880 shares of IONS stock, worth $2.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69,880
Previous 68,270 2.36%
Holding current value
$2.47 Million
Previous $3.25 Million 13.96%
% of portfolio
0.0%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.06 - $51.86 $64,496 - $83,494
1,610 Added 2.36%
69,880 $2.8 Million
Q2 2024

Aug 13, 2024

BUY
$36.45 - $47.7 $544,927 - $713,115
14,950 Added 28.04%
68,270 $3.25 Million
Q1 2024

May 14, 2024

BUY
$42.03 - $53.55 $294,630 - $375,385
7,010 Added 15.14%
53,320 $2.31 Million
Q1 2023

May 15, 2023

SELL
$33.58 - $41.2 $288,149 - $353,537
-8,581 Reduced 15.63%
46,310 $1.66 Million
Q4 2022

Feb 13, 2023

BUY
$37.12 - $46.52 $838,021 - $1.05 Million
22,576 Added 69.86%
54,891 $2.07 Million
Q3 2022

Nov 14, 2022

BUY
$36.54 - $48.66 $272,040 - $362,273
7,445 Added 29.94%
32,315 $1.43 Million
Q1 2022

May 16, 2022

SELL
$29.88 - $37.04 $103,384 - $128,158
-3,460 Reduced 12.21%
24,870 $921,000
Q4 2021

Feb 11, 2022

BUY
$25.61 - $35.1 $725,531 - $994,383
28,330 New
28,330 $862,000
Q1 2021

May 12, 2021

SELL
$42.51 - $63.78 $207,533 - $311,373
-4,882 Closed
0 $0
Q4 2020

Feb 12, 2021

SELL
$45.3 - $60.27 $235,469 - $313,283
-5,198 Reduced 51.57%
4,882 $276,000
Q3 2020

Nov 12, 2020

BUY
$47.45 - $62.95 $478,296 - $634,536
10,080 New
10,080 $478,000
Q1 2020

May 11, 2020

SELL
$41.6 - $63.4 $231,878 - $353,391
-5,574 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$53.85 - $65.27 $300,159 - $363,814
5,574 New
5,574 $337,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.02B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.